T. Ueki

Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma

K. Eguchi, H. Ishikawa, K. Nakata, 1999, Gene Therapy.

Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma.

K. Migita, K. Eguchi, T. Ueki, 2005, Journal of hepatology.

Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma

K. Migita, K. Eguchi, T. Ueki, 2005 .

Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter.

K. Eguchi, H. Ishikawa, K. Nakata, 2001, Biochemical and biophysical research communications.

Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter.

K. Nakata, F. Mawatari, T. Ueki, 1998, Cancer gene therapy.

Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice.

K. Eguchi, H. Ishikawa, K. Nakata, 1998, International Journal of Molecular Medicine.

Detection of hepatitis B virus genome in hepatocellular carcinoma from both hepatitis B surface antigen- and antibody to hepatitis C virus-negative patients.

S. Nagataki, K. Nakata, F. Mawatari, 1996, Oncology reports.